Related Experiment Videos
Management of hypercalcemia in relation to pathophysiology
J P Bonjour1, R Rizzoli, S Hirschel-Scholz
1Department of Medicine, University Hospital, Geneva, Switzerland.
Bone
|January 1, 1987
Summary
Hypercalcemia of malignancy (HM) involves calcium imbalance. Treatment targets elevated bone resorption or tubular reabsorption, with specific agents like clodronate or WR-2721 depending on the primary mechanism.
Area of Science:
- Endocrinology
- Nephrology
- Oncology
Background:
- Hypercalcemia arises from disturbed calcium (Ca) balance, involving intestinal absorption, skeletal resorption, and renal excretion.
- Calciotropic hormones and cytokines can disrupt Ca fluxes, leading to excess calcium in the extracellular space.
- Hypercalcemia of malignancy (HM) often involves increased bone resorption, but enhanced tubular reabsorption can also be a key factor.
Purpose of the Study:
- To investigate the mechanisms of calcium imbalance in hypercalcemia of malignancy.
- To evaluate therapeutic strategies targeting specific calcium flux abnormalities.
- To identify optimal treatments based on whether bone resorption or tubular reabsorption is the predominant issue.
Main Methods:
- Analysis of calcium (Ca) fluxes at intestinal, skeletal, and renal tubular sites.
- Evaluation of the efficacy of clodronate, an antiresorbing agent, in normalizing bone resorption.
- Assessment of the role of tubular calcium reabsorption (TRCa) and potential inhibition by agents like WR-2721.
Main Results:
- Increased net bone resorption (BR) is common in HM.
- In some HM patients, sustained high tubular calcium reabsorption (TRCa) contributes significantly, even after saline correction.
- Clodronate effectively normalizes BR but may be insufficient when high TRCa is the primary driver.
Conclusions:
- Clodronate is the preferred treatment for HM with elevated BR and normal TRCa.
- When increased TRCa is the main mechanism, clodronate should be combined with other agents.
- WR-2721 shows potential for rapidly lowering plasma calcium in HM with high TRCa.